Literature DB >> 23287795

Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis.

Rachel Wong1, Melanie Wong, Paul D Robinson, Dominic A Fitzgerald.   

Abstract

Allergic bronchopulmonary aspergillosis [ABPA] complicates cystic fibrosis in around 10% of teenagers. Systemic corticosteroids are the mainstay of treatment but with on-going use are associated with significant side effects prompting consideration of steroid sparing therapies. The clinical courses over ten years of two children with CF complicated by steroid dependent chronic ABPA and its successful treatment with monthly omalizumab are reported.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23287795     DOI： 10.1016/j.prrv.2012.11.004

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN： 1526-0542            Impact factor:   2.726


  9 in total

Review 1.  Fungal Pathogens in CF Airways: Leave or Treat?

Authors:  A Singh; A Ralhan; C Schwarz; D Hartl; A Hector
Journal:  Mycopathologia       Date:  2017-08-02       Impact factor: 2.574

2.  Quantum chemical calculation and binding modes of H1R; a combined study of molecular docking and DFT for suggesting therapeutically potent H1R antagonist.

Authors:  Yasir Mohamed Riza; Md Rimon Parves; Fahmida Alam Tithi; Sanjida Alam
Journal:  In Silico Pharmacol       Date:  2019-02-25

Review 3.  Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.

Authors:  Carsten Schwarz; Dominik Hartl; Olaf Eickmeier; Andreas Hector; Christian Benden; Isabelle Durieu; Amparo Sole; Silvia Gartner; Carlos E Milla; Peter James Barry
Journal:  Mycopathologia       Date:  2017-07-31       Impact factor: 2.574

4.  Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.

Authors:  Rodrigo Abensur Athanazio; Luiz Vicente Ribeiro Ferreira da Silva Filho; Alberto Andrade Vergara; Antônio Fernando Ribeiro; Carlos Antônio Riedi; Elenara da Fonseca Andrade Procianoy; Fabíola Villac Adde; Francisco José Caldeira Reis; José Dirceu Ribeiro; Lídia Alice Torres; Marcelo Bicalho de Fuccio; Matias Epifanio; Mônica de Cássia Firmida; Neiva Damaceno; Norberto Ludwig-Neto; Paulo José Cauduro Maróstica; Samia Zahi Rached; Suzana Fonseca de Oliveira Melo
Journal:  J Bras Pneumol       Date:  2017 May-Jun       Impact factor: 2.624

Review 5.  Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  Ibrahim Ahmed Janahi; Abdul Rehman; Amal Rashid Al-Naimi
Journal:  Ann Thorac Med       Date:  2017 Apr-Jun       Impact factor: 2.219

6.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162

Review 7.  Allergic Bronchopulmonary Aspergillosis.

Authors:  Michael C Tracy; Caroline U A Okorie; Elizabeth A Foley; Richard B Moss
Journal:  J Fungi (Basel)       Date:  2016-06-06

8.  Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  Moshe Ashkenazi; Saray Sity; Ifat Sarouk; Bat El Bar Aluma; Adi Dagan; Yael Bezalel; Lea Bentur; Kris De Boeck; Ori Efrati
Journal:  J Asthma Allergy       Date:  2018-06-19

Review 9.  Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis.

Authors:  Birce Sunman; Dilber Ademhan Tural; Beste Ozsezen; Nagehan Emiralioglu; Ebru Yalcin; Uğur Özçelik
Journal:  Front Pediatr       Date:  2020-10-20       Impact factor: 3.418
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.